0001387131-20-007592.txt : 20200817
0001387131-20-007592.hdr.sgml : 20200817
20200817090300
ACCESSION NUMBER: 0001387131-20-007592
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200813
FILED AS OF DATE: 20200817
DATE AS OF CHANGE: 20200817
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEDERMAN SETH
CENTRAL INDEX KEY: 0001563420
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36019
FILM NUMBER: 201108066
MAIL ADDRESS:
STREET 1: C/O TONIX PHARMACEUTICALS HOLDING CORP
STREET 2: 509 MADISON AVE., SUITE 306
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp.
CENTRAL INDEX KEY: 0001430306
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261434750
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 509 MADISON AVE. - SUITE 1608
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 1-800-849-7894
MAIL ADDRESS:
STREET 1: 509 MADISON AVE. - SUITE 1608
CITY: NEW YORK
STATE: NY
ZIP: 10022
FORMER COMPANY:
FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC.
DATE OF NAME CHANGE: 20080320
4
1
lederman-form4_0813020.xml
OWNERSHIP DOCUMENT
X0306
4
2020-08-13
0
0001430306
Tonix Pharmaceuticals Holding Corp.
TNXP
0001563420
LEDERMAN SETH
C/O TONIX PHARMACEUTICALS HOLDING CORP
509 MADISON AVE., SUITE 306
NEW YORK
NY
10022
1
1
0
0
Chief Executive Officer
Common Stock, $0.001 par value
2020-08-13
4
P
0
60000
0.91
A
83267
I
By 401(k) plan
Common Stock, $0.001 par value
459
I
By IRA Account
Common Stock, $0.001 par value
177
D
Common Stock, $0.001 par value
31
I
By spouse
Common Stock, $0.001 par value
30
I
By Leder Laboratories, Inc.
Common Stock, $0.001 par value
30
I
By Starling Pharmaceuticals, Inc.
Common Stock, $0.001 par value
205
I
By Lederman & Co., LLC
Common Stock, $0.001 par value
33
I
By L&L Technologies, LLC
Common Stock, $0.001 par value
59
I
By Targent Pharmaceuticals, LLC
Reporting person may be deemed to be a control person of this entity.
/s/ Seth Lederman
2020-08-17